Schweizer SGU 1-6

Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology

Retrieved on: 
星期二, 三月 26, 2024
LPA, Microbiology, Metabolism, CD8, LPAR, LPAR5, Lab, Inflammation, Research, Immunology, ATX, Cancer, University, Fibrosis, Schweizer SGU 1-6, Vaccine

The collaboration will focus on exploring the potential of BBT-877, a novel autotaxin (ATX) inhibitor, as an immuno-oncology treatment for cancer.

Key Points: 
  • The collaboration will focus on exploring the potential of BBT-877, a novel autotaxin (ATX) inhibitor, as an immuno-oncology treatment for cancer.
  • "We are excited to collaborate with Dr. Torres's Lab to investigate the potential of BBT-877 as a novel immuno-oncology treatment," said James Lee, CEO of Bridge Biotherapeutics.
  • Under the terms of the collaboration, Bridge Biotherapeutics will provide financial support and access to BBT-877, while Dr. Raul Torres's Lab will contribute its expertise in immunology and cancer biology.
  • Together, the two entities will conduct preclinical studies to evaluate the therapeutic potential of BBT-877 in enhancing anti-tumor immunity.

Moleculin Announces Presentation of Positive Pharmacokinetics and Tissue-Organ Distribution Data Demonstrating High Antitumor Activity of Annamycin in Preclinical Cancer Models

Retrieved on: 
星期二, 四月 18, 2023
Orange County Convention Center, DOX, AACR, Liver disease, Hepatocellular carcinoma, ANN, Schweizer SGU 1-6, MIA, Survival, Pharmacokinetics, American Association for Cancer Research, Research, Experiment, Hyperrectangle, MD Anderson Cancer Center, Plasma, Death, Animal, American Society for Pharmacology and Experimental Therapeutics, Division, University, Proteasome inhibitor, Doxorubicin, Topoisomerase, Mouse, Liver, HEPA, Anthracycline, Therapy, LC/MS, Virus, HCC, Medical imaging, Pharmaceutical industry

HOUSTON, April 18, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that positive preclinical data regarding the Company's next-generation anthracycline, Annamycin, was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL. This research was sponsored by the Company.

Key Points: 
  • "Annamycin has continued to demonstrate in preclinical models promising results in hard-to-treat tumors.
  • The high antitumor activity seen preclinically with Annamycin is very encouraging and provides validation for expanded studies to assess activity in different tumor liver metastasis models as well as HCC models," commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin .
  • The antitumor efficacy of L-ANN was studied using HEPA 1-6 hepatocellular carcinoma models (subcutaneous, orthotopic, and experimental liver metastatic models) as well as CT26 colon cancer and MIA PaCa-2 pancreatic cancer liver metastasis models.
  • Unless specifically noted otherwise, references to "Annamycin" refer to the liposome formulated form of the drug.